Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas
Neuroendocrinology · 2023
DOI: 10.1159/000529710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroendocrinology, 2023. Verfasst von Francesca Pecori Giraldi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: ACTH-Secreting Pituitary Adenoma, Pituitary ACTH Hypersecretion, Adenoma, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The glucocorticoid receptor is pivotal to control corticotrophin (ACTH) secretion, and its function is closely linked to the heat shock protein 90 (HSP90) chaperone complex. Impaired sensitivity to glucocorticoid feedback is a hallmark of human corticotroph adenomas, i.e., Cushing’s disease, a disorder with few medical treatment options. Silibinin, a HSP90 inhibitor, has been studied in tumoral corticotroph cells and its use proposed in Cushing’s disease. Aim of the present study was to further investigate the effect of silibinin on human corticotroph adenomas in vitro.
Methods
Seven human ACTH-secreting pituitary adenomas were established in culture and treated with 10–50 µm silibinin with/without dexamethasone for up to 72 h. ACTH medium levels were measured, and POMC and glucocorticoid receptor, i.e., NR3C1, gene expression assessed.
Results
Silibinin reduced spontaneous ACTH secretion and restored sensitivity to steroid negative feedback to a different extent in individual adenomas. POMC expression was decreased in both control and dexamethasone-treated wells in specimens sensitive to silibinin. Interestingly, silibinin reduced constitutive NR3C1 expression and reversed the dexamethasone-induced inhibition.
Conclusions
Our findings indicate that silibinin can inhibit ACTH synthesis and secretion in individual human corticotroph adenomas and directly affects NR3C1 gene expression. These results reveal promising effects of this HSP90 inhibitor on human corticotroph adenomas and support an innovative target treatment for patients with Cushing’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- Neuroendocrine Research Laboratory, Istituto Auxologico Italiano IRCCS, Milan, Italy.
- Department of Neurosurgery, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.
- Department of Neurosurgery, Ospedale San Raffaele IRCCS, Milan, Italy.
Zitieren
APA
Pecori Giraldi, F., Cassarino, M. F., Sesta, A., Lasio, G., & Losa, M. (2023). Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas. Neuroendocrinology. https://doi.org/10.1159/000529710
Vancouver
Pecori Giraldi F, Cassarino MF, Sesta A, Lasio G, Losa M. Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas. Neuroendocrinology. 2023. doi:10.1159/000529710
BibTeX
@article{PecoriGiraldi2023,
author = {Pecori Giraldi, Francesca and Cassarino, Maria Francesca and Sesta, Antonella and Lasio, Giovanni and Losa, Marco},
title = {Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas},
journal = {Neuroendocrinology},
year = {2023},
doi = {10.1159/000529710}
}
EUVIMED